Credit Suisse analyst Lorenzo Biasio maintained a Hold rating on Edwards Lifesciences (EW – Research Report) yesterday and set a price target of $78.00. The company’s shares closed yesterday at $79.09.
According to TipRanks, Biasio is a 4-star analyst with an average return of 5.5% and a 59.07% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Boston Scientific, Coherus Biosciences, and Edwards Lifesciences.
In addition to Credit Suisse, Edwards Lifesciences also received a Hold from Raymond James’s Jayson Bedford in a report issued yesterday. However, on February 1, Evercore ISI maintained a Buy rating on Edwards Lifesciences (NYSE: EW).
See Insiders’ Hot Stocks on TipRanks >>
Based on Edwards Lifesciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.35 billion and a net profit of $398.4 million. In comparison, last year the company earned a revenue of $1.33 billion and had a net profit of $335.3 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
Read More on EW:
- Early notable gainers among liquid option names on February 1st
- Edwards Lifesciences price target raised to $76 from $68 at Canaccord
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
- Edwards Lifesciences sees Q1 adjusted EPS 58c-64c, consensus 59c
- Edwards Lifesciences backs FY23 adjusted EPS $2.45-$2.60, consensus $2.50
